Comments
Loading...

CRISPR Therapeutics Analyst Ratings

CRSPNASDAQ
Logo brought to you by Benzinga Data
$41.22
0.050.12%
At close: -
$41.35
0.130.32%
After Hours: Mar 21, 7:25 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$120.00
Lowest Price Target1
$30.00
Consensus Price Target1
$71.68

CRISPR Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRSP | Benzinga

CRISPR Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for CRISPR Therapeutics Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Oct 24
1
1
Nov 24
1
Dec 24
2
Jan
7
3
1
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citigroup
Morgan Stanley
Evercore ISI Group
Goldman Sachs
JMP Securities

1calculated from analyst ratings

Analyst Ratings for CRISPR Therapeutics

Buy NowGet Alert
02/19/2025Buy NowCantor Fitzgerald
Eric Schmidt31%
ReiteratesNeutral → NeutralGet Alert
02/18/2025Buy NowCitigroup
Yigal Nochomovitz55%
$89 → $82MaintainsBuyGet Alert
02/14/2025Buy NowMorgan Stanley
Terence Flynn66%
$30 → $32MaintainsUnderweightGet Alert
02/14/2025Buy NowEvercore ISI Group
Liisa Bayko70%
$60 → $99UpgradeIn-Line → OutperformGet Alert
02/13/2025Buy NowGoldman Sachs
Salveen Richter52%
$66 → $57MaintainsNeutralGet Alert
02/13/2025Buy NowJMP Securities
Silvan Tuerkcan46%
$86 → $86ReiteratesMarket Outperform → Market OutperformGet Alert
02/13/2025Buy NowStifel
Benjamin Burnett46%
$53 → $49MaintainsHoldGet Alert
02/13/2025Buy NowHC Wainwright & Co.
Mitchell Kapoor45%
$65 → $65ReiteratesBuy → BuyGet Alert
02/13/2025Buy NowChardan Capital
Geulah Livshits46%
$94 → $84MaintainsBuyGet Alert
02/12/2025Buy NowTruist Securities
Joon Lee78%
$100 → $120MaintainsBuyGet Alert
02/12/2025Buy NowRBC Capital
Luca Issi40%
$53 → $48MaintainsSector PerformGet Alert
02/12/2025Buy NowNeedham
Gil Blum51%
$84 → $84ReiteratesBuy → BuyGet Alert
02/12/2025Buy NowBarclays
Gena Wang50%
$55 → $56MaintainsEqual-WeightGet Alert
02/03/2025Buy NowHC Wainwright & Co.
Mitchell Kapoor45%
→ $65Initiates → BuyGet Alert
01/14/2025Buy NowNeedham
Gil Blum51%
$84 → $84ReiteratesBuy → BuyGet Alert
01/07/2025Buy NowB of A Securities
Geoff Meacham63%
$98 → $85MaintainsBuyGet Alert
12/20/2024Buy NowJMP Securities
Silvan Tuerkcan46%
$86 → $86ReiteratesMarket Outperform → Market OutperformGet Alert
12/10/2024Buy NowChardan Capital
Geulah Livshits46%
$94 → $94MaintainsBuyGet Alert
11/06/2024Buy NowRBC Capital
Luca Issi40%
$53 → $53ReiteratesSector Perform → Sector PerformGet Alert
11/06/2024Buy NowBarclays
Gena Wang50%
$59 → $55MaintainsEqual-WeightGet Alert
11/06/2024Buy NowNeedham
Gil Blum51%
$84 → $84ReiteratesBuy → BuyGet Alert
10/04/2024Buy NowRBC Capital
Luca Issi40%
$60 → $53MaintainsSector PerformGet Alert
08/12/2024Buy NowTruist Securities
Joon Lee78%
$120 → $100MaintainsBuyGet Alert
08/08/2024Buy NowCantor Fitzgerald
Eric Schmidt31%
Reiterates → NeutralGet Alert
08/06/2024Buy NowStifel
Benjamin Burnett46%
$60 → $59MaintainsHoldGet Alert
08/06/2024Buy NowBarclays
Gena Wang50%
$67 → $59MaintainsEqual-WeightGet Alert
08/06/2024Buy NowRBC Capital
Luca Issi40%
$66 → $60MaintainsSector PerformGet Alert
08/06/2024Buy NowChardan Capital
Geulah Livshits46%
$112 → $94MaintainsBuyGet Alert
08/06/2024Buy NowNeedham
Gil Blum51%
$88 → $84MaintainsBuyGet Alert
06/28/2024Buy NowGuggenheim
Debjit Chattopadhyay54%
Assumes → NeutralGet Alert
06/27/2024Buy NowNeedham
Gil Blum51%
$88 → $88ReiteratesBuy → BuyGet Alert
06/17/2024Buy NowPiper Sandler
Edward Tenthoff52%
$105 → $105ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy NowNeedham
Gil Blum51%
$88 → $88ReiteratesBuy → BuyGet Alert
05/23/2024Buy NowCitigroup
Yigal Nochomovitz55%
$89 → $84MaintainsBuyGet Alert
05/10/2024Buy NowOppenheimer
Jay Olson62%
$102 → $95MaintainsOutperformGet Alert
05/09/2024Buy NowJMP Securities
Silvan Tuerkcan46%
$86 → $86ReiteratesMarket Outperform → Market OutperformGet Alert
05/09/2024Buy NowWells Fargo
Yanan Zhu36%
$70 → $65MaintainsEqual-WeightGet Alert
05/09/2024Buy NowCantor Fitzgerald
Eric Schmidt31%
Reiterates → NeutralGet Alert
05/09/2024Buy NowBarclays
Gena Wang50%
$80 → $67MaintainsEqual-WeightGet Alert
05/09/2024Buy NowNeedham
Gil Blum51%
$90 → $88MaintainsBuyGet Alert
05/09/2024Buy NowBaird
Jack Allen 36%
$46 → $52MaintainsNeutralGet Alert
04/18/2024Buy NowCitigroup
Yigal Nochomovitz55%
$88 → $89MaintainsBuyGet Alert
04/11/2024Buy NowNeedham
Gil Blum51%
$90 → $90ReiteratesBuy → BuyGet Alert
03/06/2024Buy NowMizuho
Salim Syed45%
$82 → $99MaintainsBuyGet Alert
02/26/2024Buy NowMorgan Stanley
Terence Flynn66%
$46 → $48MaintainsUnderweightGet Alert
02/22/2024Buy NowRBC Capital
Luca Issi40%
$57 → $66MaintainsSector PerformGet Alert
02/22/2024Buy NowWells Fargo
Jim Birchenough61%
$55 → $70MaintainsEqual-WeightGet Alert
02/22/2024Buy NowBarclays
Gena Wang50%
$61 → $80MaintainsEqual-WeightGet Alert
02/22/2024Buy NowChardan Capital
Geulah Livshits46%
$110 → $112MaintainsBuyGet Alert
02/21/2024Buy NowNeedham
Gil Blum51%
$88 → $90MaintainsBuyGet Alert
02/15/2024Buy NowWolfe Research
Andy Chen39%
Initiates → Peer PerformGet Alert
12/11/2023Buy NowRBC Capital
Luca Issi40%
$50 → $57MaintainsSector PerformGet Alert
12/11/2023Buy NowTruist Securities
Joon Lee78%
$220 → $160MaintainsBuyGet Alert
12/11/2023Buy NowBarclays
Gena Wang50%
$56 → $61MaintainsEqual-WeightGet Alert
12/11/2023Buy NowTD Cowen
Tyler Van Buren48%
→ $30DowngradeMarket Perform → UnderperformGet Alert
12/11/2023Buy NowJMP Securities
Silvan Tuerkcan46%
$74 → $80MaintainsMarket OutperformGet Alert
12/11/2023Buy NowNeedham
Gil Blum51%
$85 → $88MaintainsBuyGet Alert
12/08/2023Buy NowTruist Securities
Joon Lee78%
→ $220ReiteratesBuy → BuyGet Alert
12/08/2023Buy NowMizuho
Salim Syed45%
→ $82ReiteratesBuy → BuyGet Alert
12/05/2023Buy NowJMP Securities
Silvan Tuerkcan46%
→ $74ReiteratesMarket Outperform → Market OutperformGet Alert
11/13/2023Buy NowMorgan Stanley
Terence Flynn66%
$43 → $42MaintainsUnderweightGet Alert
11/07/2023Buy NowRBC Capital
Luca Issi40%
$55 → $50MaintainsSector PerformGet Alert
11/07/2023Buy NowNeedham
Gil Blum51%
$88 → $85MaintainsBuyGet Alert
11/01/2023Buy NowNeedham
Gil Blum51%
→ $88ReiteratesBuy → BuyGet Alert
10/30/2023Buy NowNeedham
Gil Blum51%
→ $88ReiteratesBuy → BuyGet Alert
10/17/2023Buy NowCantor Fitzgerald
Eric Schmidt31%
DowngradeOverweight → NeutralGet Alert
09/27/2023Buy NowMizuho
Salim Syed45%
→ $82Initiates → BuyGet Alert
08/18/2023Buy NowCitigroup
Yigal Nochomovitz55%
→ $70UpgradeNeutral → BuyGet Alert
08/17/2023Buy NowCitigroup
Yigal Nochomovitz55%
→ $70UpgradeNeutral → BuyGet Alert
08/14/2023Buy NowMorgan Stanley
Terence Flynn66%
$42 → $43MaintainsUnderweightGet Alert
08/10/2023Buy NowOppenheimer
Jay Olson62%
→ $102ReiteratesOutperform → OutperformGet Alert
08/08/2023Buy NowCredit Suisse
Richard Law45%
$62 → $63MaintainsNeutralGet Alert
08/08/2023Buy NowEF Hutton
Tony Butler43%
→ $75ReiteratesBuy → BuyGet Alert
08/08/2023Buy NowNeedham
Gil Blum51%
→ $88ReiteratesBuy → BuyGet Alert
08/08/2023Buy NowChardan Capital
Geulah Livshits46%
$123 → $110MaintainsBuyGet Alert
07/25/2023Buy NowJMP Securities
Silvan Tuerkcan46%
→ $74ReiteratesMarket Outperform → Market OutperformGet Alert
06/09/2023Buy NowNeedham
Gil Blum51%
$82 → $88ReiteratesBuy → BuyGet Alert
06/09/2023Buy NowJMP Securities
Silvan Tuerkcan46%
$70 → $74MaintainsMarket OutperformGet Alert
06/09/2023Buy NowEF Hutton
Tony Butler43%
→ $75Reiterates → BuyGet Alert
06/01/2023Buy NowBarclays
Gena Wang50%
$61 → $64MaintainsEqual-WeightGet Alert
05/30/2023Buy NowWilliam Blair
Sami Corwin11%
→ $75Reinstates → OutperformGet Alert
05/23/2023Buy NowCitigroup
Yigal Nochomovitz55%
$55 → $70MaintainsNeutralGet Alert
05/12/2023Buy NowMorgan Stanley
Terence Flynn66%
$39 → $42MaintainsUnderweightGet Alert
05/09/2023Buy NowRBC Capital
Luca Issi40%
→ $50Reiterates → Sector PerformGet Alert
05/09/2023Buy NowJMP Securities
Silvan Tuerkcan46%
→ $70Reiterates → Market OutperformGet Alert
05/09/2023Buy NowCredit Suisse
Richard Law45%
$65 → $62MaintainsNeutralGet Alert
05/09/2023Buy NowStifel
Benjamin Burnett46%
$69 → $64MaintainsHoldGet Alert
05/09/2023Buy NowNeedham
Gil Blum51%
→ $82Reiterates → BuyGet Alert
04/20/2023Buy NowNeedham
Gil Blum51%
→ $82Reiterates → BuyGet Alert
04/17/2023Buy NowJMP Securities
Silvan Tuerkcan46%
→ $70Reiterates → Market OutperformGet Alert
04/17/2023Buy NowEF Hutton
Tony Butler43%
→ $75Reiterates → BuyGet Alert
04/13/2023Buy NowCantor Fitzgerald
Olivia Brayer63%
→ $72Initiates → OverweightGet Alert
04/03/2023Buy NowEF Hutton
Tony Butler43%
→ $75Reiterates → BuyGet Alert
03/21/2023Buy NowBernstein
William Pickering44%
→ $44Initiates → Market PerformGet Alert
03/18/2023Buy NowCitigroup
Yigal Nochomovitz55%
$63 → $55MaintainsNeutralGet Alert
03/07/2023Buy NowBaird
Jack Allen 36%
→ $46Initiates → NeutralGet Alert
02/27/2023Buy NowJMP Securities
Silvan Tuerkcan46%
→ $70Reiterates → Market OutperformGet Alert
02/27/2023Buy NowMorgan Stanley
Terence Flynn66%
$37 → $39MaintainsUnderweightGet Alert
02/23/2023Buy NowOppenheimer
Jay Olson62%
$110 → $102.06MaintainsOutperformGet Alert
02/22/2023Buy NowChardan Capital
Geulah Livshits46%
$153 → $123MaintainsBuyGet Alert

FAQ

Q

What is the target price for CRISPR Therapeutics (CRSP) stock?

A

The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Cantor Fitzgerald on February 19, 2025. The analyst firm set a price target for $0.00 expecting CRSP to fall to within 12 months (a possible -100.00% downside). 43 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?

A

The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Cantor Fitzgerald, and CRISPR Therapeutics reiterated their neutral rating.

Q

When was the last upgrade for CRISPR Therapeutics (CRSP)?

A

The last upgrade for CRISPR Therapeutics AG happened on February 14, 2025 when Evercore ISI Group raised their price target to $99. Evercore ISI Group previously had an in-line for CRISPR Therapeutics AG.

Q

When was the last downgrade for CRISPR Therapeutics (CRSP)?

A

The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.

Q

When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

Q

Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?

A

While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $0.00 to $0.00. The current price CRISPR Therapeutics (CRSP) is trading at is $41.35, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.